Found: 7
Select item for more details and to access through your institution.
Compliance with Good Manufacturing Practice in the Assessment of Immunomodulation Potential of Clinical Grade Multipotent Mesenchymal Stromal Cells Derived from Wharton's Jelly.
- Published in:
- Cells (2073-4409), 2019, v. 8, n. 5, p. 484, doi. 10.3390/cells8050484
- By:
- Publication type:
- Article
Multi-component cord blood banking: a proof-of-concept international exercise.
- Published in:
- Blood Transfusion (17232007), 2023, v. 21, n. 6, p. 526, doi. 10.2450/BloodTransfus.492
- By:
- Publication type:
- Article
Cord blood-derived platelet concentrates as starting material for new therapeutic blood components prepared in a public cord blood bank: from product development to clinical application.
- Published in:
- Blood Transfusion (17232007), 2020, v. 18, n. 3, p. 208, doi. 10.2450/2020.0305-19
- By:
- Publication type:
- Article
Clinical translation of a mesenchymal stromal cell‐based therapy developed in a large animal model and two case studies of the treatment of atrophic pseudoarthrosis.
- Published in:
- Journal of Tissue Engineering & Regenerative Medicine, 2018, v. 12, n. 1, p. e532, doi. 10.1002/term.2323
- By:
- Publication type:
- Article
Successful treatment of post‐transplant CMV meningoencephalitis with third‐party CMV virus‐specific T cells: Lessons learned.
- Published in:
- Pediatric Transplantation, 2019, v. 23, n. 8, p. N.PAG, doi. 10.1111/petr.13584
- By:
- Publication type:
- Article
Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use.
- Published in:
- Immunologic Research, 2023, v. 71, n. 5, p. 725, doi. 10.1007/s12026-023-09385-1
- By:
- Publication type:
- Article
Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells.
- Published in:
- Stem Cell Research & Therapy, 2022, v. 13, n. 1, p. 1, doi. 10.1186/s13287-022-02961-6
- By:
- Publication type:
- Article